187 related articles for article (PubMed ID: 24618769)
21. Use of SERMs for treatment in postmenopausal women.
Pinkerton JV; Thomas S
J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
[TBL] [Abstract][Full Text] [Related]
22. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
23. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV
Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
[TBL] [Abstract][Full Text] [Related]
24. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study.
Shufelt C; Bairey Merz CN; Pettinger MB; Choi L; Chlebowski R; Crandall CJ; Liu S; Lane D; Prentice R; Manson JE;
Menopause; 2018 Sep; 25(9):985-991. PubMed ID: 29738414
[TBL] [Abstract][Full Text] [Related]
25. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
26. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
Komm BS; Mirkin S; Jenkins SN
Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
[TBL] [Abstract][Full Text] [Related]
27. From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition.
Valera MC; Gourdy P; Trémollières F; Arnal JF
Maturitas; 2015 Nov; 82(3):274-7. PubMed ID: 26261036
[TBL] [Abstract][Full Text] [Related]
28. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.
Stovall DW
Curr Opin Investig Drugs; 2010 Apr; 11(4):464-71. PubMed ID: 20336595
[TBL] [Abstract][Full Text] [Related]
29. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
[TBL] [Abstract][Full Text] [Related]
30. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
31. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
Jackson RD; Wactawski-Wende J; LaCroix AZ; Pettinger M; Yood RA; Watts NB; Robbins JA; Lewis CE; Beresford SA; Ko MG; Naughton MJ; Satterfield S; Bassford T;
J Bone Miner Res; 2006 Jun; 21(6):817-28. PubMed ID: 16753012
[TBL] [Abstract][Full Text] [Related]
32. Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen.
Yue W; Wang J; Atkins KA; Bottalico L; Mesaros C; Blair IA; Santen RJ
Int J Cancer; 2018 Sep; 143(5):1259-1268. PubMed ID: 29577272
[TBL] [Abstract][Full Text] [Related]
33. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
[TBL] [Abstract][Full Text] [Related]
34. Treating menopausal symptoms with a tissue-selective estrogen complex.
Levine JP
Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
[TBL] [Abstract][Full Text] [Related]
35. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women.
Palacios S; Mejía Ríos A
Drugs Today (Barc); 2015 Feb; 51(2):107-16. PubMed ID: 25756066
[TBL] [Abstract][Full Text] [Related]
36. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys.
Ethun KF; Wood CE; Register TC; Cline JM; Appt SE; Clarkson TB
Menopause; 2012 Nov; 19(11):1242-52. PubMed ID: 23103754
[TBL] [Abstract][Full Text] [Related]
37. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review.
Nelson HD
JAMA; 2004 Apr; 291(13):1610-20. PubMed ID: 15069049
[TBL] [Abstract][Full Text] [Related]
38. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
[TBL] [Abstract][Full Text] [Related]
39. Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
Mirkin S; Komm B; Pickar JH
Womens Health (Lond); 2014 Mar; 10(2):135-46. PubMed ID: 24601804
[TBL] [Abstract][Full Text] [Related]
40. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
Tella SH; Gallagher JC
Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
